Advances in pharmacological and clinical studies of vascular endothelial growth factor inhibitors in the treatment of retinal angiomatous proliferation
Retinal angiomatous proliferation(RAP)is a type of eye disease caused by angiogenesis.Microhemangioma is formed due to the imbalance of vascular growth factors and vascular inhibitory factors,which can seriously affect the visual acuity of patients.High expression of vascular endothelial growth factor(VEGF)can accelerate the development of RAP,and anti-VEGF can accelerate tumor atrophy and improve clinical efficacy.Currently,known anti-VEGF drugs include ranibizumab,bevacizumab and aflibercept,etc.In recent years,the role of anti-VEGF in RAP therapy has attracted much attention.This article reviewed the mechanism of VEGF in RAP and the progress of anti-VEGF therapy,aiming to provide clinical reference.
NETL
NSTL
万方数据
